|
Cost-effectivenes study of renal sympathetic denervation published. |
 |
 |
|
Medgadget: A new article published in the Journal of the American College of Cardiology suggests that the Medtronic renal denervation system, Symplicity, is a cost-effective strategy for treatment-resistant Hypertension. Currently, the Symplicity system is only available for investigational use in the United States. The statistical model used suggests that incorporating Standard of Care medication therapy, including 3 or greater medications, with renal denervation could potentially reduce cardiovascular mortality by 30% and all-cause mortality by 15% when compared to Standard of Care alone.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
